Objective. To assess the relationships between systemic IFN type I (IFN-I) and II (IFN-II) activity and disease manifestations in primary SS (pSS).
Introduction
Primary SS (pSS) is characterized by lymphocytic infiltrations in salivary and lachrymal glands. This is accompanied by sicca symptoms and frequently also extraglandular manifestations [13] . Treatment is mainly symptomatic, and biologics so far have shown limited efficacy.
IFNs play a pivotal role in the pathogenesis of pSS. The presence of IFN-induced gene expression has been demonstrated in the salivary glands, peripheral blood mononuclear cells, isolated monocytes and B cells of pSS patients [48] . This so-called IFN type I signature was associated with higher disease activity and higher levels of autoantibodies [9] . Recent findings also show activation of IFN type II-induced gene expression in salivary glands of pSS patients [10, 11] . To our knowledge detailed analysis of modular IFN type I and II activation patterns in a large cohort of pSS patients has not been performed.
Type I and II IFN bind to different receptors, but induce partially overlapping gene expression patterns. Therefore, it is difficult to determine which type of IFN triggers the IFN-induced gene expression pattern observed in pSS. However, understanding the relative contribution of IFN type I and II may deepen our knowledge in pSS pathogenesis and promote a stratified approach to therapeutic development.
Systemic type I IFN activation has been extensively characterized in SLE. In clinical trials blocking of IFN type I had limited efficacy, possibly due to unopposed type II IFN activation [1214] . In SLE, Chiche et al. have reported three strongly upregulated IFN-annotated modules (M1.2, M3.4 and M5.12) from peripheral blood transcriptomic data. Each of these modules has a distinct activation threshold [15] . The M1.2 transcriptional module was induced by IFNa, while both M1.2 and M3.4 transcripts were upregulated by IFNb. M5.12 was poorly induced by IFNa and IFNb alone. Transcripts belonging to M3.4 and M5.12 were only fully induced by a combination of type I and II IFNs and displayed a more dynamic pattern when studied over time in SLE. Interestingly, M5.12 was mainly upregulated in SLE patients with high disease activity and correlated with renal flares. These data indicate that detailed modular analysis for pSS can contribute to the discovery of better biomarkers and development of stratified therapeutic intervention.
Fatigue is a major complaint in pSS patients [1620] and is associated with a poor quality of life [21] . Patients receiving IFNa treatment for viral hepatitis can develop severe fatigue [22] and in rare cases also develop pSSlike symptoms [2325]. Here we investigate a possible correlation between IFN activation and fatigue.
In this study, we performed a detailed analysis, using the IFN annotated modules described for SLE, in two large clinically well-characterized pSS cohorts-the United Kingdom Primary Sjö gren's Syndrome Registry (UKPSSR) and the Rotterdam (The Netherlands) cohort. Furthermore, we assessed the relationships between these IFN modules and fatigue as well as other clinical features.
Methods

Patient recruitment
PSS patients and healthy controls (HCs) from the UK cohort were from the UKPSSR collected in 30 centres [26] . PSS patients and HC from the Rotterdam cohort were recruited at the Erasmus Medical Centre, Rotterdam, The Netherlands. All pSS patients fulfilled the 2002 AmericanEuropean Consensus Group classification criteria [27] . Disease activity was assessed using EULAR Sjö gren's Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI) [28, 29] . HCs did not suffer from autoimmune disease or use corticosteroid. Characteristics of patients are summarized in supplementary Table S1 , available at Rheumatology online. Written informed consent was obtained from all participants in the study, in compliance with the Declaration of Helsinki. The Medical Ethical Review Committee of the Erasmus MC and North West Research Ethics Committee approved this study.
Blood collection, measurement of laboratory parameters and RT-PCR Blood was collected in clotting tubes for serum preparation and in PAXgene RNA tubes (PreAnalytix, Hombrechtikon, Switzerland) for whole blood RNA analysis. RNA isolation, cDNA preparation and RT-PCR were performed according to the manufacturer's protocol. See supplementary methods, available at Rheumatology online, for extended protocols.
Calculation of IFN score for each module
To identify correlated groups of genes and reduce data complexity, the expression of IFN-inducible genes (from M1.2, M3.4 and M5.12) was added to a principle component analysis. KaiserMeyerOlkin measure of sampling adequacy were respectively 0.882, 0.907 and 0.888 for M1.2, M3.4 and M5.12. In order to assess the amount of variance explained by each factor, eigenvalues were extracted.
The IFN score for each module was defined by the relative expression of five indicator genes. For M1.2 these genes were IFI44, IFI44L, IFIT1, IFIT3 and MxA; for M3.4, ZBP1, EIFAK2, IFIH1, PARP9 and GBP4; and for M5.12, PSMB9, NCOA7, TAP1, ISG20 and SP140. Mean and S.D. HC of each gene in the HC group were used to standardize expression levels. IFN scores per subject represent the sum of these standardized scores, calculated as previously described [32, 33] . Patients were divided into groups that were positive or negative for M1.2, M3.4 or M5.12, using a threshold of mean HC + 2 Â S.D. HC.
Assessment of fatigue and depressive symptoms
In the UK cohort, fatigue was assessed using the profile of fatigue and discomfort-Sicca symptoms inventory (PROFAD-SSI), visual analogue scale (VAS) for fatigue and the EULAR Sjö gren's syndrome patient reported index (ESSPRI) [28, 34, 35] . In the Rotterdam cohort fatigue was assessed using the Dutch version of the multidimensional fatigue inventory (MFI) [36] . Depressive symptoms were assessed using the hospital anxiety and depression scale (HADS) for the UK cohort and the Dutch-validated Center for Epidemiologic Studies Depression scale (CES-D) for the Rotterdam cohort [37, 38] .
Statistics
An independent t test was used to compare means and the MannWhitney U test was used to compare medians. Categorical data were compared using Fisher's exact test and correlations were assessed using Spearman's rho (r s ). Multiple group comparisons were analysed using one-way analysis of variance (ANOVA) or the KruskalWallis test. For extended statistics see supplementary methods, available at Rheumatology online.
Results
Presence of IFN annotated modules in whole blood of pSS patients
To select five indicator genes for each of the previously described IFN annotated modules (M1.2, M3.4 and M5.12) [15] , 1116 genes were selected using micro-array data of differentially expressed genes in monocytes of pSS patients (supplementary Table S2 , available at Rheumatology online; unpublished results, Versnel et al.) [4] . Expression levels of these genes were assessed in 50 pSS patients and 38 HCs (Rotterdam cohort) using RT-PCR and added into a principle component analysis to identify correlated groups of genes in order to reduce data complexity.
Five indicator genes for each module were selected and subsequently determined in a cohort of 86 pSS patients (UK cohort), followed by a replication cohort of 55 pSS patients (Rotterdam cohort). A flow chart summarizing this selection procedure is shown in supplementary Fig. S1 , available at Rheumatology online. All IFN annotated modular scores were expressed significantly higher in pSS patients than in HCs (supplementary Fig. S2 , available at Rheumatology online). Furthermore, the three IFN modules strongly correlated with each other as depicted for the UK and Rotterdam cohorts combined (P < 0.001) (Fig. 1A) .
To study the modular expression over time, the modular IFN scores of 15 pSS patients of the Rotterdam cohort were determined at two different time points. The mean (S.D.) period between two time points was 1.8 (0.8) years. There were no significant differences in M1.2 and M3.4 score between the two time points. In the M5.12 module there was a significant difference in score between the two time points (Fig. 1B) .
Of the M1.2 positive patients, 9096% were also positive for M3.4 and 6667% were also positive for M5.12 when both cohorts were combined. Only three patients were positive for M3.4 while negative for M1.2 and M5.12. There were no patients positive for M5.12 and negative for M1.2.
In the UK cohort 81, 78, 55, 53 and 19% of the patients were positive for M1.2, M3.4, M5.12, all the modules and none of the modules, respectively (Fig. 1C) Fig. 2AC ). Schirmer's test scores were significantly lower in IFN type I + II positive patients compared with patients without IFN activation (UK cohort: Table 1 and Fig. 2F ).
Systemic upregulation of IFN-inducible genes is associated with higher biological disease parameters but not clinical ESSDAI To investigate differences in disease activity between patients without, with IFN type I-and with IFN type I + II-inducible gene expression, the ESSDAI and its subdomains were compared between the different subgroups. The frequency of pSS patients positive for the biological domain was higher in patients with IFN activation compared with patients without IFN activation (UK cohort: Table 2;  Rotterdam cohort: supplementary Table S4 , available at Rheumatology online). In fact, activity in the biological domain is largely confined to the IFN active groups. The frequency of pSS patients positive for the haematological domain was higher in patients with IFN type I + II-inducible gene expression compared with patients without IFN-inducible gene expression or with only IFN type I-inducible gene expression in the UK cohort. There were no differences in total-ESSDAI or ClinESSDAI scores between the different subgroups. (Table 3 ). There were no differences in fatigue, depression or anxiety between the pSS subgroups.
Discussion
In this study, we show the presence of systemic upregulation of IFN type I and IFN type I + II signatures in two Wilcoxon signed-rank test to compare dependent medians. Categorical data were compared using Fisher's exact test. * Represents P value of < 0.05, ** represents P value of < 0.005, *** represents P value of < 0.0005. were used to compare multiple groups. Asterisks represent P-values: *P < 0.05, **P < 0.005, ***P < 0.0005. I + II-inducible gene expression were more often positive for the biological domain of the ESSDAI and had higher levels of IgG, higher ESR and lower lymphocyte counts in the UK cohort. In the Rotterdam cohort IgG levels of patients with IFN type I + II were also higher compared with HCs and there was a trend towards lower lymphocyte counts. There were no differences in patient-reported fatigue or depression between patients with and without systemic IFN activation. We have previously shown systemic IFN activation in peripheral blood monocytes in a subset of pSS patients [9] . This type I IFN signature correlated with higher anti-SSA/anti-SSB autoantibody frequencies and hypergammaglobulinaemia. Comparison of these genes with the modules we tested in this study revealed that the IFN type I signature genes we used were all of the M1.2 module and thus type I induced. Indeed all patients positive for M1.2 were previously found to have a positive monocytic IFN signature [9] .
Until now no detailed studies on the presence of a systemic IFN type II signature in pSS have been performed. A recent study in pSS has reported the presence of systemic type II IFN-induced gene expression, although using different genes from this study [39] . Similar percentages of types I and I + II positive patients were reported. However, 6.8% of the patients were exclusively positive for type II IFNs; in contrast, we did not find patients only positive for M5.12. This difference could be explained by the selection of GBP1 as a gene mainly induced by IFN type II. According to the modular analysis, which our study was based upon, this gene belongs to the M3.4 module and therefore can also be induced by IFNb.
The distribution of the modular IFN expression we detect in pSS is very similar to that earlier described for SLE. In pSS as well as SLE, M1.2 is the most prevalent module followed by M3.4 and M5.12 [15] . Additionally, similar to SLE, in pSS patients M5.12 was never upregulated without concomitant upregulation of M1.2 and M3.4. In SLE 87% of the patients showed upregulation of at least one of the modules. In our study 81% in the UK cohort was positive for at least one of the modules and in the Rotterdam cohort 53%. Longitudinal data indicated that in both diseases M5.12 is the module most susceptible to change over time, although our data are based upon a small sample number. A difference between SLE and pSS is that the M3.4 module largely overlaps with the M1.2 in pSS, while in SLE patients this was not observed [15] . The IFN modules correlated with auto-antibodies, anti-dsDNA titres in SLE and anti-SSA/anti-SSB in pSS. M5.12 in SLE correlated with SELENA-SLEDAI scores, flares and the cutaneous domain, and in pSS this module weakly correlated with the pulmonary and renal domain of the ESSDAI (data not shown) in the UK cohort, but not the total-ESSDAI scores. A reason why we did not detect significant differences in total-ESSDAI or most ESSDAI domain scores in pSS could be because extraglandular manifestations in pSS are less frequent than in SLE. Alternatively, IFN activity may be linked only to some but not all extraglandular manifestations.
Anti-inflammatory drugs can affect IFN signatures [40] . In this study, the frequency of patients positive for the modular IFN scores was lower in the Rotterdam cohort compared with the UK cohort. One possible explanation for this could be that patients in the Rotterdam cohort were treated more often with HCQ than patients in the UK cohort. We have shown before that patients treated with HCQ have lower IFN type I scores [40] . In addition, HCQ has been shown to impare IFNa production by plasmacytoid dendritic cells (pDCs) [41] . In this study, we also stratified patients based on HCQ use. Although there appeared to be a trend toward lower IFN type I (M1.2) scores among those taking HCQ, there were no significant differences detected in any of the modular scores. However, this is a cross-sectional study with no data on pre-treatment IFN scores. Moreover, because of the contribution of other IFNs in pSS the overall effect of HCQ may not result in a significant difference in IFN score. Consistently, in SLE it was shown that HCQ treatment only lowered expression of MxA, with other interferon-inducible genes such as OAS1 and IFI27 being unaffected [42] .
Interestingly, there were no significant differences in total-ESSDAI or ClinESSDAI scores between patients without or with type I or type I + II IFN activation, except for the biological domain. This could have significant implications for selection of primary endpoints in clinical trials evaluating novel therapies. For instance, therapies targeting type I or II IFN may improve ESSDAI biological domain score, but have no impact on total-ESSDAI or ClinESSDAI scores. It is also of interest that systemic IFN activity is not associated with disease activity in other ESSDAI organ domains. One possible explanation is that the sample size in this study did not have the power to detect such differences. Another intriguing possibility is that mechanisms other than systemic IFN activation might be responsible for the clinical manifestations in these other organ domains.
Recently, salivary gland analysis of pSS patients revealed a predominant type II activation pattern [11, 39] . Comparing these data with our results on systemic IFN activation we conclude that systemically IFN type I expression dominated over IFN type II expression. This indicates that local and systemic IFN activation patterns within the same patient may differ. Future study of IFN activation patterns in paired samples from peripheral blood and salivary gland tissue of the same patient would be of interest and might help to define the role for systemic IFN activation as a biomarker for pSS.
Blocking systemic IFNa activation in SLE showed a reduction of SELENA-SLEDAI scores in a small subset of patients [13, 14, 43] . Interestingly, post hoc analysis revealed a possible effect in patients with low baseline IFN activity. This might be due to a contribution of IFN type II or IFNb to the pathogenic process. A recent study targeting the Interferon type I receptor (IFNAR) in SLE patients with moderate-to-severe disease showed encouraging clinical effectivity in patients with a high IFN signature at baseline, while patients with low IFN signatures did not respond differently compared with the placebo group [44] . Our findings here in pSS and earlier finding in SLE show distinct activation patterns (IFNa, IFNb and/or IFN type II) which all lead to upregulation of IFN-inducible genes. Stratification of patients based on their IFN activation pattern will identify subgroups that are most likely to benefit from a specific targeted treatment. For instance, patients positive for M1.2 and M3.4 could benefit from blocking the IFNAR, while in patients additionally positive for M5.12, blocking the IFN type II pathway (as well as IFNAR blockade) might be necessary.
In contrast to our hypothesis, patients with IFN activation were not more fatigued than those without IFN signatures. This might be caused by the relatively low patient number or the subjective nature of fatigue. However, our data are in line with our previous study showing no correlation between IFN type I score and visual analogue scale fatigue score [45] . Additionally, we showed for the UK cohort lower levels of pro-inflammatory cytokines, among them IFN type II, in highly fatigued pSS patients [46] . These data indicate that fatigue is not directly related to activation of IFN-induced gene expression.
This study has several limitations. First is the study of gene expression levels in peripheral blood cells, instead of in a specific cell type. However, we previously investigated the IFN type I signature in monocytes of pSS patients and identified the same set of signature genes as here in whole blood cells. Also, all patients positive for the monocytic IFN signature were also positive for M1.2 when whole blood cells were collected simultaneously. Another limitation is that the Rotterdam cohort is collected in an academic reference centre and therefore may have a disproportionately higher percentage of atypical pSS patients while the UK cohort is a national biobank with 30 recruitment centres. This may also explain the differences in the prevalence of renal complications between the two cohorts.
Taken together, this study describes the prevalence of systemic (IFN types I and/or type II) activation in pSS. Stratification according to this activation pattern revealed differences in disease features. These data raise the possibility that the biological-ESSDAI rather than total-ESSDAI score may be a more sensitive end point for trials targeting either type I or type II IFN pathway.
